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1 	 | 	 BACKGROUND
The	terms	of	reference	for	the	working	group	were	to	re-
view	the	evidence	on	lower	carbohydrate	diets	(alongside	
higher	fat	and/or	higher	protein)	compared	with	the	cur-
rent	 government	 advice	 for	 adults	 with	 type	 2	 diabetes	
(T2D);	consider	the	impact,	 in	adults	with	T2D,	of	lower	
compared	with	higher	carbohydrate	diets	on	markers	and	
clinical	outcomes	of	T2D	including	any	potential	adverse	
effects	 and	 make	 recommendations	 based	 on	 the	 review	
of	the	evidence.	Its	remit	did	not	include	consideration	of	
the	wider	management	of	T2D,	studies	of	children,	people	
with	pre-	diabetes,	type	1	diabetes	or	gestational	diabetes.
2 	 | 	 DIABETES
Diabetes	 is	a	condition	 in	which	 the	body	does	not	pro-
duce	sufficient	insulin	to	regulate	blood	glucose	levels	and	
the	insulin	produced	does	not	work	effectively.	This	leads	
to	 elevated	 blood	 glucose	 concentrations	 (hyperglycae-
mia)	which	causes	damage	to	blood	vessels	and	nerves.
There	are	two	main	types	of	diabetes:	type	1	diabetes	
and	T2D.	There	are	also	other	 forms	such	as	gestational	
diabetes	 and	 rare	 genetic	 forms	 such	 as	 maturity-	onset	
diabetes	of	 the	young.	 In	2018,	an	estimated	4·7 million	
people	 in	 the	 UK	 had	 diabetes.3	 This	 included	 about	
3.8  million	 people	 with	 diagnosed	 diabetes	 and	 an	 esti-
mated	1 million	people	who	were	undiagnosed.
T2D	accounts	for	about	90%	of	all	cases	of	diabetes	in	
the	UK3–	5	and	occurs	as	a	result	of	reduced	β-	cell	insulin	
secretion	and	increased	insulin	resistance.6	Although	sev-
eral	 non-	modifiable	 risk	 factors	 such	 as	 age,	 family	 his-
tory	and	ethnicity	are	associated	with	increased	T2D	risk,	
about	80%–	85%	of	an	individual's	risk	of	developing	T2D	
is	associated	with	obesity,7	a	modifiable	risk	factor.
2.1	 |	 Current UK government advice
Current	UK	government	advice	on	carbohydrate	 intake	 is	
based	 on	 recommendations	 made	 by	 Scientific	 Advisory	
Committee	 on	 Nutrition	 (SACN)	 following	 its	 review	 on	
carbohydrates	and	health.8	The	evidence	considered	in	the	
SACN	 review	 on	 carbohydrates	 comprised	 studies	 in	 the	
general	population,	and	recommendations	were	for	the	UK	
general	population.
Current	 UK	 government	 advice	 for	 the	 general	 pop-
ulation	is	that	approximately	50%	of	total	dietary	energy	
should	 be	 obtained	 from	 carbohydrates,	 mainly	 from	
starchy	 foods	 consisting	 of	 high	 fibre	 or	 whole-	grain	
food	where	possible.	It	is	recommended	that	the	average	
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population	intake	of	free	sugars	should	not	exceed	5%	of	
total	dietary	energy	and	that	adults	should	achieve	a	daily	
dietary	fibre	intake	of	30 g/day.
There	 are	 no	 separate	 recommendations	 on	 carbohy-
drate	 intake	 for	 adults	 with	T2D,	 and	 the	 advice	 for	 the	
general	UK	population	thus	applies	to	those	with	T2D.
In	England,	 the	National	 Institute	 for	Health	and	Care	
Excellence	has	issued	guidelines	for	the	identification,	diag-
nosis	and	management	of	T2D	including	dietary	advice	that	
is	in	line	with	UK	government	advice	for	the	general	pop-
ulation.9	 The	 Scottish	 Intercollegiate	 Guidelines	 Network	
has	also	 issued	guidelines	on	the	management	of	diabetes	
including	offering	adults	with	T2D	a	range	of	dietary	options	
for	achieving	weight	loss	that	may	also	improve	glycaemic	
control.10
The	ultimate	aim	of	T2D	management	and	treatment	is	
to	reduce	and	maintain	glycated	haemoglobin	(HbA1c)	con-
centration	at	a	value	below	the	cut-	off	for	the	definition	of	
T2D.	However,	any	reduction	in	HbA1c	reflects	an	improve-
ment	in	the	degree	of	T2D	control.	Improvement	of	blood	
lipids	and	blood	pressure	is	also	an	important	treatment	goal.
Management	of	T2D	usually	involves	behavioural	inter-
ventions	(including	diet,	physical	activity,	smoking	cessation	
and	reduced	alcohol	intake)	and/or	medications.	Treatment	
may	also	include	bariatric	surgery	to	reduce	weight.
A	reduction	in	energy	intake	is	an	important	part	of	the	
behavioural	interventions	recommended	to	people	with	T2D	
who	 are	 living	 with	 overweight	 or	 obesity.	 The	 aim	 of	 re-
ducing	energy	intake	is	weight	loss,	which	in	turn	improves	
glycaemic	control.	Glycaemic	 index	and	glycaemic	 load	are	
measures	of	the	post-	prandial	blood	glucose	response	to	foods.
Both	 Diabetes	 UK	 and	 the	 American	 Diabetes	
Association	emphasise	tailoring	advice	to	the	individual,	
and	both	note	the	lack	of	clear	evidence	for	a	specific	di-
etary	intake	of	carbohydrate	for	those	with	T2D.11,12
2.2	 |	 Purpose of review
SACN	initiated	this	evidence	review	in	response	to	a	re-
quest	 from	 Public	 Health	 England,	 for	 a	 systematic	 as-
sessment	of	the	scientific	evidence	on	‘low’-	carbohydrate	
diets,	in	recognition	that	such	diets	are	gaining	attention	
and	increasingly	being	promoted.
3 	 | 	 METHODS
SACN’s	 Framework	 for	 the	 Evaluation	 of	 Evidence2	 was	
used	as	the	basis	for	assessing	the	evidence.	Public	Health	
England	 conducted	 a	 search	 of	 key	 online	 databases:	
MEDLINE,	 Embase,	 the	 Cochrane	 Library	 (CDSR	 and	
DARE),	National	Institute	for	Health	and	Care	Excellence	
evidence,	 TRIP	 and	 Google	 Scholar	 to	 identify	 relevant	
English	 language	articles	published	between	1980	and	30	
September	2018,	using	an	agreed	list	of	search	terms	focus-
ing	on	lower	carbohydrate	diets	and	T2D.	There	was	a	par-
ticular	interest	in	the	following	primary	outcomes:	weight	
change	 (≥12  months),	 glycated	 Hb	 (HbA1c),	 a	 marker	 of	
impaired	 glycaemic	 control	 (≥3  months)	 and	 secondary	
outcomes:	body	weight	(≥3	to	<12 months),	fasting	plasma	
glucose	(≥3 months),	blood	lipid	profiles	(≥3 months)	and	
medication	use.
SACN	invited	interested	parties	to	highlight	relevant	ev-
idence	which	satisfied	the	inclusion	criteria	for	the	report	
through	 a	 call	 for	 evidence	 from	 9	 February	 to	 7  March	
2018.
The	 report	 included	 evidence	 from	 systematic	 reviews	
(SR)	and	meta-	analyses	(MA)	and	pooled	analyses	of	ran-
domised	 controlled	 trials	 (RCT)	 and	 prospective	 cohort	
studies	 comparing	 the	 impact	 of	 lower	 vs	 higher	 carbo-
hydrate	diets	on	markers	and	clinical	outcomes	of	T2D.	It	
also	included	RCT	published	after	the	most	recent	SR,	MA	
and	pooled	analyses	of	RCT.2	Only	SR	that	included	stud-
ies	with	a	minimum	duration	of	3 months	and	individuals	
with	 pre-	diagnosed	T2D	 (as	 defined	 in	 the	 primary	 RCT)	
when	they	entered	the	study	were	considered.	Two	review-
ers	independently	screened	titles	and	abstracts	of	the	publi-
cations	identified	by	the	literature	search	and	subsequently	
assessed	full-	text	articles.	Any	differences	were	resolved	by	
consensus.
For	the	purposes	of	this	report,	in	order	to	enable	com-
parisons	of	carbohydrate	intake	across	the	studies	under	
consideration,	 the	 classification	 proposed	 by	 Feinman	
et	al.13	was	adopted	as	the	basis	for	the	categorisation	of	
carbohydrate	intake	(see	Table 1).
The	quality	of	included	SR	and	MA	was	assessed	by	the	ap-
proach	outlined	in	the	SACN	Framework	for	the	Evaluation	
of	Evidence2	and	the	AMSTAR	2	tool.14	Expert	judgement,	
based	on	pre-	specified	criteria,	was	used	to	grade	the	strength	
of	the	evidence	(adequate,	moderate,	limited,	inconsistent	or	
insufficient)	for	the	primary	and	secondary	outcomes.	Only	
outcomes	where	the	evidence	base	was	graded	as	adequate	
or	moderate	were	used	to	inform	recommendations.
T A B L E  1 	 Categories	of	dietary	carbohydrate	intakes	based	on	
Feinman	et	al.	(2015)13	and	Accurso	et	al.	(2008)19
Description
Amount of carbohydrate
g/d
% TE (based on 
2000 kcal/d)
Very	low	carbohydratea 20–	50 ≤10
Low	carbohydrate >50	to	<130 >10	to	<26
Moderate	carbohydrate 130–	230 26–	45
High	carbohydrate >230 >45
aAlso	referred	to	as	ketogenic	diets.
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3.1	 |	 Evidence identified
After	 the	 removal	 of	 duplicates,	 the	 online	 database	
search	 identified	 3169	 abstracts	 that	 were	 screened	 for	
eligibility.	 Full	 texts	 of	 nineteen	 potentially	 relevant	 SR	
with	 MA	 were	 retrieved	 and	 assessed.	 Out	 of	 these,	 15	
were	excluded.	Five	additional	publications	that	met	the	
inclusion	criteria	were	identified	by	SACN	working	group	
members.	In	total,	nine	publications	met	the	criteria	and	
were	included	for	data	extraction,	including	eight	SR	with	
MA	and	one	network	meta-	analysis.
After	a	detailed	assessment,	results	from	four	SR	with	
MA15–	18	were	used	 to	grade	 the	evidence	and	draw	con-
clusions.	 This	 is	 because	 they	 were	 more	 recent,	 had	
larger	numbers	of	participants	and	were	considered	to	be	
of	better	quality	based	on	 the	SACN	Framework	 for	 the	
Evaluation	 of	 Evidence2	 and	 AMSTAR	 2	 criteria.14	 Out	
of	 the	 36	 publications	 included	 in	 the	 MA,	 18	 reported	
outcomes	 in	 the	 shorter	 term	 (minimum	 duration	 of	
3  months)	 only	 and	 18	 reported	 outcomes	 in	 the	 longer	
term	 (minimum	 duration	 of	 12  months).	 In	 this	 report,	
shorter term	refers	to	studies	or	assessments	that	reported	
at	≥3	 to	 6  months	 (since	 all	 except	 1	 of	 the	 time	 points	
included	 in	 shorter-	term	 studies	 or	 assessments	 did	 not	
extend	beyond	6 months)	and	longer term	refers	to	studies	
that	reported	outcomes	at	≥12 months.
Body	weight
The	 evidence	 for	 lower	 compared	 with	 higher	 carbohy-
drate	diets	on	body	weight	was	inconsistent	in	the	shorter	
term	(≥3	 to	6 months);	 there	was	a	greater	 reduction	 in	
body	weight	with	 lower	compared	with	higher	carbohy-
drate	 diets	 at	 3  months,	 but	 this	 difference	 was	 not	 ob-
served	 between	 3	 and	 6  months	 or	 at	 6  months.	 There	
was	adequate	evidence	for	no	difference	in	effect	between	
lower	 and	 higher	 carbohydrate	 diets	 in	 reducing	 body	
weight	in	the	longer	term	(≥12 months).
HbA1c
There	was	adequate	 evidence	of	a	greater	 reduction	 in	
HbA1c	with	lower	compared	with	higher	carbohydrate	
diets	in	the	shorter	term	(≥3	to	6 months).	The	evidence	
was	inconsistent	in	longer-	term	studies	with	a	duration	
of	 12	 up	 to	 24  months.	 There	 was	 adequate	 evidence	
for	 no	 difference	 between	 lower	 and	 higher	 carbohy-
drate	diets	on	HbA1c	change	 in	 longer-	term	studies	at	
24 months.
Fasting	plasma	glucose
There	was	moderate	evidence	of	a	greater	reduction	 in	
fasting	 plasma	 glucose	 with	 lower	 compared	 with	 the	
higher	 carbohydrate	 diets	 in	 the	 shorter	 term	 (≥3	 to	
6  months).	 There	 was	 insufficient	 evidence	 to	 assess	 if	
there	 was	 a	 difference	 between	 lower	 and	 higher	 car-
bohydrate	diets	on	fasting	plasma	glucose	in	the	longer	
term	(≥12 months).
Serum	total	cholesterol
There	 was	 moderate	 evidence	 for	 no	 difference	 in	 effect	
between	lower	and	higher	carbohydrate	diets	in	reducing	
serum	total	cholesterol	in	the	shorter	term	(≥3	to	6 months).	
There	 was	 adequate	 evidence	 for	 no	 difference	 in	 effect	
between	lower	and	higher	carbohydrate	diets	in	reducing	
serum	total	cholesterol	in	the	longer	term	(≥12 months).
Serum	TAG
There	 was	 adequate	 evidence	 of	 a	 greater	 reduction	 in	
serum	 TAG	 with	 lower	 compared	 with	 higher	 carbohy-
drate	diets	in	the	shorter	term	(≥3	to	6 months).	The	evi-
dence	was	inconsistent	in	the	longer	term	(≥12 months).
Serum	LDL-	cholesterol
There	 was	 adequate	 evidence	 for	 no	 difference	 in	 effect	
between	lower	and	higher	carbohydrate	diets	on	change	
in	 serum	 LDL-	cholesterol	 in	 the	 shorter	 term	 (≥3	 to	
6 months)	and	in	the	longer	term	(≥12 months).
Serum	HDL-	cholesterol
The	 evidence	 on	 lower	 compared	 with	 higher	 carbohy-
drate	 diets	 on	 serum	 HDL-	cholesterol	 was	 inconsistent	
in	 the	 shorter	 term	 (≥3	 to	 6  months)	 and	 longer	 term	
(≥12 months).
Changes	in	medication	use
There	was	moderate	evidence	of	a	greater	reduction	in	med-
ication	use	with	lower	compared	with	higher	carbohydrate	
diets.	This	outcome	was	not	assessed	according	to	study	du-
ration.	It	was	not	possible	to	assess	consistency	in	effect	size.
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3.2	 |	 Limitations of the evidence base
The	overall	quality	of	the	evidence	base	was	limited	by	a	
number	of	uncertainties	in	the	data,	including	variabil-
ity	in	the	definition	of	a	low-	carbohydrate	diet;	smaller	
than	 prescribed	 differences	 in	 reported	 carbohydrate	
intakes	 between	 lower	 and	 higher	 carbohydrate	 diets;	
inherent	 inaccuracies	 in	 estimates	 of	 self-	reported	 di-
etary	 intakes	 and	 lack	 of	 information	 on	 adherence	 to	
prescribed	diets.
An	important	limitation	was	that	the	risk	of	bias	was	
high	or	unclear	in	most	of	the	primary	RCT	that	was	in-
cluded	 in	 the	MA.	This	 reduces	 the	confidence	 that	can	
be	placed	on	the	estimates	of	the	effects	of	lower	carbohy-
drate	diets	on	the	markers	of	T2D	and	clinical	outcomes	
under	consideration.
Another	important	limitation	in	the	evidence	base	was	
that	shorter-	term	studies	did	not	assess	outcomes	beyond	
6 months	and	few	longer-	term	studies	assessed	outcomes	
beyond	12 months.
The	majority	of	participants	in	the	primary	RCT	were	
living	with	overweight	(BMI	≥	25	to	<30 kg/m2)	or	obesity	
(BMI	≥	30 kg/m2).	It	is	not	known	if	reported	effects	can	
be	generalised	to	adults	with	a	healthy	weight	(BMI	≥	18·5	
to	<25 kg/m2).
It	is	not	known	if	the	reported	effects	of	lower	carbohy-
drate	diets	apply	to	individuals	of	different	ethnicities	since	
the	majority	of	primary	RCT	did	not	report	the	ethnicity	of	
participants	and	most	were	conducted	in	populations	that	
were	 predominantly	 White.	 In	 those	 that	 were	 reported	
ethnicity,	 none	 conducted	 subgroup	 analyses	 based	 on	
ethnicity.
This	 report	 did	 not	 assess	 evidence	 on	 the	 effect	 of	
lower	carbohydrate	diets	in	the	general	population	with-
out	T2D.	It	 is	not	known	if	 the	reported	effects	of	 lower	
carbohydrate	diets	in	adults	with	T2D	apply	to	the	general	
adult	population	without	T2D.
Several	additional	gaps	were	identified	in	the	evidence	
base:
•	 No	trials	provided	information	about	the	type	of	carbo-
hydrate	consumed	(e.g.	wholegrain,	refined	grain,	free	
sugars,	 fibre)	 or	 considered	 how	 this	 could	 affect	 the	
outcomes	of	interest;
•	 The	 potential	 impact	 of	 increasing	 the	 proportions	 of	
other	 macronutrients	 (usually	 fats	 and/or	 proteins)	
to	 compensate	 for	 reduced	 carbohydrate	 intake	 in	 the	
lower	carbohydrate	groups,	or	the	type	of	macronutri-
ent	(e.g.	saturated	or	unsaturated	fats;	plant-	or	animal-	
based	 proteins),	 on	 markers	 and	 clinical	 outcomes	 of	
T2D	was	generally	not	considered;	and
•	 No	trials	considered	clinical	endpoints	such	as	diabetes	
complications,	CVD	events	or	mortality.
3.3	 |	 Conclusions
Overall,	 the	evidence	suggests	beneficial	effects	of	 lower	
carbohydrate	 diets	 for	 some	 outcomes	 (HbA1c,	 fasting	
plasma	 glucose,	 serum	 TAG)	 in	 the	 shorter	 term	 (up	 to	
6 months).	Since	the	shorter-	term	assessments	did	not	re-
port	outcomes	between	6	and	12 months,	it	is	uncertain	if	
the	suggested	benefits	are	maintained	beyond	6 months.
Although	there	was	no	consistent	evidence	of	reductions	
in	body	weight	with	lower	carbohydrate	diets,	it	is	not	possi-
ble,	from	the	evidence	considered,	to	separate	the	effects	of	
weight	change	from	effects	of	change	in	carbohydrate	intake.
Lower	carbohydrate	diets	may	allow	reductions	in	dia-
betes	medication,	but	the	interpretation	is	complicated	by	
inconsistencies	in	reporting	and	measurement	of	changes	
in	medication	use.
No	 differences	 were	 observed	 between	 higher	
and	 lower	 carbohydrate	 diets	 on	 serum	 total	 or	 LDL-	
cholesterol	either	in	the	shorter	(≥3	to	6 months)	or	longer	
term	(≥12 months).	Evidence	on	HDL-	cholesterol	was	in-
consistent	in	the	shorter	(≥3	to	6 months)	and	longer	term	
(≥12 months).
In	general,	 there	was	no	difference	 in	adverse	events	
between	 lower	 and	 higher	 carbohydrate	 diets	 but	 study	
duration	did	not	extend	beyond	12 months	in	the	majority	
of	primary	RCT.
3.4	 |	 Recommendations
The	report	states	that	recommendations	are	applicable	to	
adults	 living	 with	 T2D	 and	 overweight	 or	 obesity.	 There	
was	 insufficient	 evidence	 to	 make	 recommendations	 for	
adults	living	with	T2D	without	being	overweight	or	obesity.	
The	 report	did	not	assess	evidence	on	 the	effect	of	 lower	
carbohydrate	diets	in	the	general	population	without	T2D.
The	report	makes	the	following	recommendations:
•	 For	adults	 living	with	T2D	and	overweight	or	obesity,	 a	
lower	carbohydrate	diet	can	be	recommended	by	clinicians	
as	an	effective	short-	term	option	(up	to	6 months)	for	im-
proving	glycaemic	control	and	serum	TAG	concentrations.
•	 Individuals	living	with	T2D	and	overweight	or	obesity	
who	 choose	 a	 lower	 carbohydrate	 diet	 should	 include	
whole-	grain	or	higher	fibre	foods,	a	variety	of	fruits	and	
vegetables	and	limit	intakes	of	saturated	fats,	reflecting	
current	dietary	advice	for	the	general	population.
•	 Since	the	majority	of	individuals	living	with	T2D	have	
overweight	or	obesity,	weight	management	remains	the	
primary	 goal	 for	 improving	 glycaemic	 control	 and	 re-
ducing	CVD	risk.	Health	professionals	should	support	
any	evidence-	based	dietary	approach	that	helps	individ-
uals	with	T2D	to	achieve	long-	term	weight	reduction.
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•	 Adults	living	with	T2D	and	overweight	or	obesity	who	
change	to	a	lower	carbohydrate	diet	and	are	taking	di-
abetes	medication	may	be	at	risk	of	hypoglycaemia.	It	
is	 recommended	 that	 they	 receive	 advice	 and	 support	
from	their	health	care	team	to	manage	this	risk	and	to	
make	adjustments	to	their	medication	as	required.
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